How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/relapsed-or-refractory-follicular-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Relapsed or refractory follicular lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relapsed or refractory follicular lymphoma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Relapsed or refractory follicular lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lunsumio	MOSUNETUZUMAB	Roche		B-lymphocyte antigen CD20	2022-01-01
Pf-07985631	pf-07985631	Pfizer	Unknown	Unknown
LUNSUMIO	MOSUNETUZUMAB-AXGB	GENENTECH INC		B-lymphocyte antigen CD20

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

GENENTECH INC · 1 drug in Relapsed or refractory follicular lymphoma
Pfizer · 1 drug in Relapsed or refractory follicular lymphoma
Roche · 1 drug in Relapsed or refractory follicular lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Relapsed or refractory follicular lymphoma:

Cite this brief

Drug Landscape (2026). Relapsed or refractory follicular lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapsed-or-refractory-follicular-lymphoma. Accessed 2026-06-10.

Relapsed or refractory follicular lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing